Hot Pursuit     18-Sep-20
Shilpa Medicare gains after board OKs setting up unit in Malaysia
Shilpa Medicare rose 1.64% to Rs 592.20 after the company said its board approved forming a wholly-owned subsidiary in Malaysia.

The stock has added 5.6% in three sessions while the benchmark S&P BSE Sensex shed 0.46% during the same period.

On the technical front, the stock's RSI (relative strength index) stood 60.422. The RSI oscillates between zero and 100. Traditionally the RSI is considered overbought when above 70 and oversold when below 30.

The stock is currently trading above its 50-day, 100-day and 200-day simple moving average (SMA) placed at 558.65, 501.16 and 418.84, respectively.

Shilpa Medicare is a global brand in manufacturing and supplying of affordable API and formulation globally in different regulated markets.

The company's consolidated net profit surged 474.7% to Rs 85.98 crore on 38.4% jump in net sales to Rs 222.86 crore in Q1 June 2020 over Q1 June 2019. EBITDA margin improved to 31% in Q1 FY21 compared with 19% in Q1 FY20.

Previous News
  Sensex declines 150 pts; realty shares slide for 5th day
 ( Market Commentary - Mid-Session 04-Oct-24   10:32 )
  Shilpa Medicare arm gets CEP from EDQM for Desmopressin
 ( Hot Pursuit - 04-Oct-24   08:40 )
  Shilpa Medicare announces receipt of CEP from EDQM for API 'Desmopressin'
 ( Corporate News - 03-Oct-24   17:12 )
  Sensex gains 233 pts; private banks rally for 6th day
 ( Market Commentary - Mid-Session 19-Sep-24   14:31 )
  Shilpa Medicare arm appoints Sridevi Khambhampaty as CEO
 ( Hot Pursuit - 19-Sep-24   13:35 )
  Shilpa Biologicals appoints CEO
 ( Corporate News - 19-Sep-24   13:35 )
  Shilpa Medicare hits life high on submission of new drug application to USFDA
 ( Hot Pursuit - 04-Sep-24   15:24 )
  Shilpa Medicare update on its CDMO customer - Unicycive Therapeutics
 ( Corporate News - 04-Sep-24   15:14 )
  Shilpa Medicare hits record high on USFDA nod for cancer drug
 ( Hot Pursuit - 27-Aug-24   14:43 )
  Shilpa Medicare hits 52-week high on successful trial of fatty liver drug
 ( Hot Pursuit - 26-Aug-24   12:41 )
  Shilpa Medicare successfully completes phase-3 clinical studies of NorUDCA
 ( Corporate News - 26-Aug-24   10:30 )
Other Stories
  UCO Bank’s total advances jump 19% YoY in Q2 FY25
  04-Oct-24   15:15
  Vakrangee Ltd leads losers in 'A' group
  04-Oct-24   15:00
  Kamdhenu Ventures Ltd leads losers in 'B' group
  04-Oct-24   14:45
  GRSE bags Rs 226-cr LoA from West Bengal Govt
  04-Oct-24   14:40
  Volumes soar at Avenue Supermarts Ltd counter
  04-Oct-24   14:30
  Real Estate stocks edge lower
  04-Oct-24   14:00
  Auto stocks edge lower
  04-Oct-24   14:00
  Utilties stocks edge lower
  04-Oct-24   14:00
  HDFC Bank Ltd down for fifth straight session
  04-Oct-24   13:35
  Power Grid Corporation of India Ltd down for fifth straight session
  04-Oct-24   13:35
Back Top